top of page

Disc Medicine CEO John Quisel describes the process of becoming among the first companies to receive FDA's new Commissioner's National Priority Voucher (CNPV)

  • Oct 22, 2025
  • 1 min read

He describes how Disc applied for and was awarded a CNPV for Bitopertin, which treats a rare disease that causes extreme sensitivity to sunlight. Plus, quickly ramping up a commercial team, and discussing Disc's two other development programs.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

​

​Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page